Trial Profile
A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Andenocarcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 05 May 2019 Status changed from active, no longer recruiting to completed.
- 21 Jan 2017 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 2017 Gastrointestinal Cancers Symposium
- 21 Jan 2017 Results assessing the efficacy and safety presented at the 2017 Gastrointestinal Cancers Symposium.